Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Pharma Holdings Receives SFDA Approval for Proton Pump Inhibitor

publication date: Aug 21, 2009

China Pharma Holdings was given SFDA approval for Omeprazole Sodium injection, a proton pump inhibitor that is prescribed for gastroesophageal reflux disease (GERD) and other conditions caused by excessive stomach acid. The drug is a generic form of Losec and Prilosec, marketed by AstraZeneca. Although most Omeprazole products are oral, China Pharma’s formulation is an injection, which enters the blood circulation more quickly and avoids degradation in the stomach. More details...

Stock Symbol: (OTCBB: CPHI) (NYSE: AZN)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital